Search clinical trials for: Cabotamig (ARB202)

Total 26 results

Arbele Pty Ltd

Recruiting

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Gastric Cancer | Pancreatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Gastrointestinal Cancer | Liver Cancer | Colorectal Adenocarcinoma | Gastroesophageal Junction

Hong Kong, Australia
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aronora, Inc.

Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Thrombosis

United States
Immunobrain Checkpoint
National Institute on Aging (NIA); Alzheimer's Association

Recruiting

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Alzheimer's Disease

Israel, United Kingdom, Netherlands
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Pompe Disease Infantile-Onset

Taiwan, United States, Italy
Aronora, Inc.
Celerion

Completed

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
University of Nottingham
Nottingham University Hospitals NHS Trust

Not yet recruiting

Effect of Consuming Products Containing Rare Sugars Alongside Sucrose on Glycaemic Response in Healthy Adults

Glycaemic Response in Healthy Participants

United Kingdom
Shanghai Zerun Biotechnology Co.,Ltd

Active, not recruiting

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

COVID-19 | SARS-CoV-2 Infection

Mali
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
University Hospital Regensburg
University of Magdeburg

Terminated

Nasal High Flow at Acute Hart Failure

Decompensated Heartfailure | Cardio-renal Syndrom

Germany
HI-Bio

Recruiting

A Study of Felzartamab in Participants With Lupus Nephritis

Lupus Nephritis

United States, Argentina, Australia
TRB Chemedica International SA

Not yet recruiting

Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease (BUSTON-02)

Dry Eye Disease
Alvogen Korea

Completed

Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers

Healthy

Korea, Republic of
Alvogen Korea

Completed

Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers

Healthy

Korea, Republic of
Alvogen Korea

Completed

Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions

Healthy

Korea, Republic of
ARCA Biopharma, Inc.
Colorado Prevention Center

Completed

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN)

Covid19

United States, Argentina, Brazil
Amicus Therapeutics

Active, not recruiting

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

Pompe Disease

United States, Netherlands, United Kingdom, Australia, Germany, New Zealand
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
Amicus Therapeutics

Recruiting

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA)

Glycogen Storage Disease Type II Infantile Onset

United States, Taiwan, France, Germany, Italy, United Kingdom
Amicus Therapeutics

Recruiting

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Pompe Disease (Late-onset)

United States, Japan, Australia, Taiwan, Canada
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
Amicus Therapeutics

Recruiting

A Global Prospective Observational Registry of Patients With Pompe Disease

Pompe Disease

United States, Germany
Alvogen Korea

Completed

Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease (DAVICI)

Peripheral Arterial Disease

Search clinical trials for: Cabotamig (ARB202)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations